TTTong Tong

Tong Tong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tong Tong has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Zainab Khurshid

    Boston University Chobanian & Avedisian School of Medicine, Boston, MA USA

    3 shared publications
  • Chao Chen

    Department of Burn and Plastic Surgery, Shenzhen Key Laboratory of Microbiology in Genomic Modification & Editing and Application, Shenzhen Institute of Translational Medicine, Shenzhen University Medical School, Medical Innovation Technology Transformation Center of Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University

    2 shared publications
  • Congcong Zhu

    Boston University Chobanian & Avedisian School of Medicine, Boston, MA USA

    2 shared publications
  • Eden R. Martin

    Dr. John T. MacDonald Foundation Department of Human Genetics, University of Miami Miller School of Medicine, Miami, FL, USA

    2 shared publications
  • Fei Wang

    Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Brain Center, School of Pharmaceutical Sciences, Zhongnan Hospital, Wuhan University, Wuhan 430071, Hubei, China; Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China

    2 shared publications
  • Gerald D. Schellenberg

    University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA

    2 shared publications

Latest Publications

  • Open Access

    Identification of rare coding variants associated with Alzheimer’s disease.

    by Zainab Khurshid, Lindsay A. Farrer, Xiaoling Zhang, Eden R. Martin, Amanda B Kuzma, John Farrell, Tong Tong, Congcong Zhu, Adam C. Naj, Laura B Cantwell, et al.

    Background: Previous whole exome sequencing (WES) studies of Alzheimer’s disease (AD) have identified genome‐wide significant associations with rare variants in several novel genes and highlighted the need for investigations in larger samples. We combined WES and whole genome sequencing (WGS) data assembled by the Alzheimer Disease Sequencing Project (ADSP) to increase the power for detecting associations of AD with rare variants in gene coding regions.Method: We developed an efficient computational pipeline to perform both pre‐merging and post‐merging genotype, variant and sample‐level quality control (QC) on WGS data containing 16,905 individuals and WES data for 20,504 individuals. The resultant sample included participants from European (EA, 11,279 AD cases, 8,924 controls), African American (AA, 2,757 AD cases, 4,336 controls), and Caribbean Hispanic (CH 1,438 AD cases, 3,256 controls) ancestries. We employed GENESIS to test association of AD with 250,465 bi‐allelic QC’d variants using a logistic model including covariates for age, sex, exome capture kit, read length, and ancestry principal components (PCs).Result: In the total sample, variants from APOE and other known AD genes including SORL1 (P = 5.30×10‐7), NECTIN2 (P = 6.94×10‐7), and TREM2 R47H (P = 2.34×10‐13) crossed or neared the study‐wide significance (SWS) threshold of P = 2.00×10‐7 (0.05/250,465). SWS or borderline significant associations were also found with variants in several novel loci including TKTL2 (P = 2.35×10‐8), D2HGDH, (P = 1.09×10‐7), CECR1 (P = 4.02×10‐7), PDHA2 (P = 2.76×10‐7), GOLGA1 (P = 1.72×10‐7), CYLD (P = 1.84×10‐7), and RP11‐243M5.4 (P = 1.37×10‐7). PSEN1 missense mutation G206A (rs63750082) previously associated with early onset AD in the CH group, was significantly associated with late onset AD in the same population (P = 1.58×10‐13). SWS association of AD with APOE was observed in all groups. Significant associations were also observed with variants in SERPINB8 (P = 3.77×10‐9) and FAM171A (P = 7.20×10‐7) in EAs and TLR4 (P = 4.58×10‐7) in CH. Associations with several top‐ranked variants were replicated in the Alzheimer’s Disease Genetics Consortium GWAS dataset that were imputed using the TOPMed reference panel and ADSP 5K WGS dataset.Conclusion: We demonstrated that merging WGS and WES datasets can increase power to detect associations with rare coding variants in genes including ones previously implicated in AD (CYLD and TLR4) and early‐onset stroke (CECR1).

  • Open Access

    Blood‐derived mitochondrial DNA copy number is associated with Alzheimer’s Disease through the regulation of plasma lipid and amino acid metabolism

    by Tong Tong, Congcong Zhu, John Farrell, Zainab Khurshid, Eden R. Martin, Margaret A. Pericak‐Vance, Li‐San Wang, Gerald D. Schellenberg, Jonathan L. Haines, Kathryn L. Lunetta, et al.

    Background: Blood‐derived mitochondrial DNA copy number (mtDNA‐CN) is the proxy measurement of mitochondrial function in the peripheral and central systems. Abnormal mtDNA‐CN not only indicates impaired mtDNA replication and transcription machinery but also dysregulated biological processes such as energy and lipid metabolism. However, the relationship between mtDNA‐CN and Alzheimer’s Disease (AD) and the underlying mechanisms of mitochondrial dysfunction in the pathogenesis of AD are still unclear.Method: To investigate the causal relationship between mtDNA‐CN and AD, we performed two‐sample Mendelian randomization (MR) using publicly available summary statistics from GWAS for mtDNA‐CN and AD. Further, we estimated mtDNA‐CN using whole‐genome sequence data from blood samples of 1,521 ADNI participants and used a Cox proportional hazard model, adjusted for age, sex, and study phase, to assess the association between mtDNA‐CN and AD risk. The association of AD biomarkers measured in brain and plasma metabolites with mtDNA‐CN was evaluated using linear regression. We conducted causal mediation analysis to test the natural indirect effects of mtDNA‐CN change on AD risk through the significantly associated biomarkers and metabolites.Result: MR analysis using a profile likelihood approach suggested a causal relationship between decreased blood‐derived mtDNA‐CN and increased risk of AD (OR = 0.71; P = 0.023). Survival analysis showed that decreased mtDNA‐CN was significantly associated with increased risk of conversion from mild cognitive impairment to AD (HR = 0.80; P = 0.0017). We also identified significant associations between mtDNA‐CN and brain glucose metabolism (β = 0.050; P = 0.047) and amyloid‐β (Aβ) (β = 0.069; P = 0.015) and CSF Aβ (β = ‐0.051; P = 0.048). Plasma Aβ was, however, not associated. Several lipid species, amino acids, biogenic amines, and inflammatory proteins in plasma were also significantly associated with mtDNA‐CN. Finally, causal mediation analyses showed that the effect of change in mtDNA‐CN on AD risk is mediated by plasma neurofilament light (β = ‐0.055; P = 0.010), glycine (β = 0.016; P = 0.044), and hexadecenoylcarnitine (β = ‐0.017; P = 0.049).Conclusion: Our study indicates that mtDNA‐CN measured in blood is predictive of AD risk. Associations of mtDNA‐CN with Aβ in CSF and brain, but not plasma, suggest cross‐tissue regulation of mitochondria. Decreased mtDNA‐CN might increase AD risk through lipid and amino acid metabolism. These results also suggest potential development of mtDNA‐CN as a blood‐based biomarker.

  • Open Access

    Supplemental File 1 from The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures

    by Aaron Chevalier, Shiyi Yang, Zainab Khurshid, Nathan Sahelijo, Tong Tong, Jonathan H. Huggins, Masanao Yajima, Joshua D. Campbell

    Plate diagram and derivation of bayesian prediction algorithm

  • Synthetic Genomics: From DNA Synthesis to Genome Design

    by Lianrong Wang, Susu Jiang, Chao Chen, Wei He, Xiaolin Wu, Fei Wang, Tong Tong, Xuan Zou, Zhiqiang Li, Jie Luo, et al.

    Rapid technological advances enabling the construction of designer gene networks, biosynthetic pathways, and even entire genomes are moving the fields of genetics and genomics from descriptive to synthetic applications. Following the synthesis of small viral genomes, advances in DNA assembly and rewriting have enabled the hierarchical synthesis of bacterial genomes, such as Mycoplasma genitalium, as well as recoding of the Escherichia coli genome by reducing the number of codons from 64 to 57. The field has advanced to the point of synthesizing an entire eukaryotic genome. The Synthetic Yeast Genome Project (Sc2.0) is underway and aims to rewrite all 16 Saccharomyces cerevisiae chromosomes by 2018; to date, 6.5 chromosomes have been designed and synthesized. Using bottom‐up assembly and applying genome‐wide alterations will improve our understanding of genome structure and function. This approach will not only provide a platform for systematic studies of eukaryotic chromosomes but will also generate diverse “streamlined” strains that are potentially suitable for medical and industrial applications. Herein, we review the current state of synthetic genome research and discuss potential applications of this emerging technology.


  • Synthetische Genomik: von der DNA‐Synthese zu Designer‐Genomen

    by Lianrong Wang, Susu Jiang, Chao Chen, Wei He, Xiaolin Wu, Fei Wang, Tong Tong, Xuan Zou, Zhiqiang Li, Jie Luo, et al.

    Rasante technische Fortschritte, die die Konstruktion von genetischen Netzwerken, Biosynthesepfaden und sogar ganzer Genome ermöglichen, konvertieren derzeit die Genetik und Genomik von rein deskriptiven zu synthetischen Wissenschaften. Anknüpfend an die Synthese kleiner viraler Genome haben Fortschritte bei der Assemblierung und Neusynthese von DNA die hierarchische Synthese bakterieller Genome, z. B. von Mycoplasma genitalium, sowie die Umkodierung des Genoms von Escherichia coli durch Reduzierung der Zahl an Codons von 64 auf 57 ermöglicht. Das Gebiet ist an dem Punkt angekommen, dass wir ein gesamtes eukaryotisches Genom synthetisieren können. Das “Synthetic Yeast Genome Project” (Sc2.0) folgt den Plan, bis 2018 alle 16 Saccharomyces cerevisiae‐Chromosomen neu zu synthetisieren; bisher wurden 6.5 Chromosomen konzipiert und synthetisiert. Bottom‐up‐Assemblierung und die Anwendung genomweiter Modifikationen werden unser Verständnis der Genomstruktur und ‐funktion verbessern. Dieser Ansatz wird nicht nur eine Plattform für die systemische Erforschung eukaryotischer Chromosomen bieten, sondern auch “verschlankte” Stämme hervorbringen, die für medizinische und industrielle Anwendungen potenziell geeignet sind. In diesem Kurzaufsatz fassen wir den aktuellen Stand der Forschung im Bereich synthetischer Genome zusammen und diskutieren mögliche Anwendungen dieser neuen Technologie.